drugsTreatmentPhase 2

JK08

JK08 is an experimental fusion protein or cytokine from Salubris Biotherapeutics in phase 2 trials for melanoma, colorectal cancer and non-small-cell lung cancer, aimed at CTLA-4.

JK08 is a fusion protein or cytokine developed by Salubris Biotherapeutics. Its target is CTLA-4. ClinicalTrials.gov describes the intervention as: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma, colorectal cancer, non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma. The largest, NCT05620134, plans to enrol 263 participants with primary completion expected 2025-10-17. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How immunotherapy works, step by step · animated schematic, not to scale; chosen from the modality "fusion protein or cytokine"

Immunotherapy →

Modality

fusion protein or cytokine

Mechanism

Fusion protein or cytokine directed at CTLA-4, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

JK08

intervention: JK08

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.